Journal of Vaccines & Vaccination

The novel therapeutic mechanisms of leonurine for treating cardiac fibrosis via inhibiting FMO₂

5^th International Conference on Vaccines and Immunology & 32^nd International Conference on Cardiology and Heart Failure

MAY 23, 2022 | Webinar

Zhaoyi Li

Macau University of Science and Technology, China

Scientific Tracks Abstracts: J Vaccines Vaccin

Abstract:

Cardiovascular diseases (CVDs) are the number 1 cause of death globally, including myocardial infarction, heart failure, atherosclerosis, and myocardial hypertrophy. Heart failure (HF) is a slow, gradual and irreversible pathological process with cardiomyocyte apoptosis, the final stage of most cardiovascular diseases. The production of reactive oxygen species (ROS) can induce cardiomyocyte apoptosis, leading to cardiac dysfunction and promoting HF. Flavincontaining monooxygenase 2 (FMO2) is an enzyme closely related to oxidative stress and cardiac fibrosis. Herba leonuri (HL) is a traditional Chinese medicine with a long history of development and application in China. Recently, modern research has found that there are various chemical components in HL. However, alkaloids are the most important biologically active compounds, especially leonurine. Therefore, this manuscript studied the novel mechanisms of leonurine on HF in vitro and in vivo. Leonurine was found for the first time to inhibit the expression of FMO2 protein, which interacted in various redox reactions. Therefore, FMO2 may reduce the accumulation of ROS though its specific mechanism needs to be further studied.

Biography :

Zhaoyi Li studied at the Macau University of Science and Technology for a master's degree in Chinese Pharmacy and is engaged in cardiovascular disease and pharmacology research in the State Key Laboratory, focusing on the research of new targets for cardiovascular disease.